Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Number of subjects with treatment emergent adverse events (TEAEs) in Single Ascending Dose (SAD) compared to placebo |
An adverse event is any untoward medical occurrence in patient or clinical study participant temporarily associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; results in congenital anomaly/birth defect. AEs include both SAEs and AEs. TAEs are AEs that occur following the start of treatment or AEs increasing in severity during treatment. |
Day 1- Day 14 (From start of study medication till 14 days of last administration of study drug) |
|
Primary |
Number of subjects with clinically significant change from Baseline in vital signs in SAD |
Vital signs include blood pressure, heart rate, respiratory rate, and temperature |
Day 1-Day 14 (From start of study medication till 14 days of last administration of study drug) |
|
Primary |
Number of patients with laboratory abnormalities in SAD |
Hematology and serum chemistry |
Day 1-Day 14 (From start of study medication till 14 days of last administration of study drug) |
|
Primary |
Number of subjects with treatment emergent adverse events (TEAEs) in Multiple Ascending Dose (MAD) compared to placebo |
An adverse event is any untoward medical occurrence in patient or clinical study participant temporarily associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; results in congenital anomaly/birth defect. AEs include both SAEs and AEs. TAEs are AEs that occur following the start of treatment or AEs increasing in severity during treatment. |
Day 1-Day 11, and Follow up (after 14 days) |
|
Primary |
Number of subjects with clinically significant change from Baseline in vital signs in MAD |
Vital signs include blood pressure, heart rate, respiratory rate, and temperature |
Day 1-Day 11, and Follow up (after 14 days) |
|
Primary |
Number of patients with laboratory abnormalities in MAD |
Hematology and serum chemistry |
Day 1-Day 11, and Follow up (after 14 days) |
|
Secondary |
To collect ECG data for PBI-0451 for the purpose of concentration-QT/QTc modeling |
Criteria for clinically significant changes in ECG (12 lead) are defined as: a postdose QTc interval increase by =/>30msec from the baseline and is >450 msec; or an absolute QTc value is =/> 500 msec for any scheduled ECG. |
Day 1, 4, 6 and 11 |
|
Secondary |
Plasma concentration of each dose of study drug to determine AUCinf in SAD |
AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 to extrapolated infinite time. |
Day 1-Day 6 |
|
Secondary |
Plasma concentration of each dose of study drug to determine AUClast in SAD |
AUClast is summarized by dosing regimen and determined by linear/log trapezoidal method. |
Day 1-Day 6 |
|
Secondary |
Plasma concentration of each dose of study drug to determine %AUCexp in SAD |
%AUCexp is summarized by dosing regimen and expressed as area under the plasma concentration-time curve extrapolated from time (tau) to infinity as a percentage of total AUC |
Day 1-Day 6 |
|
Secondary |
Plasma concentration of each dose of study drug to determine CL/F in SAD |
CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological process |
Day 1-Day 6 |
|
Secondary |
Plasma concentration of each dose of study drug to determine CLss/F in MAD |
CLss/F is the total body clearance for extravascular administration divided by the fraction of dose absorbed |
Day 4, Day 6, Day 8 |
|
Secondary |
Plasma concentration of each dose of study drug to determine AUCtau in MAD |
Area under the plasma concentration- Time profile from Time zero to end of dosing interval. AUCtau is summarized by dosing regimen and period. |
Day 4, Day 6, Day 8 |
|
Secondary |
Plasma concentration of each dose of study drug to determine Cmax in MAD |
Observed Cmax is estimated based on the plasma concentrations. |
Day 4, Day 6, Day 8 (Pre dose to 24 hours) |
|
Secondary |
Plasma concentration of each dose of study drug to determine Tmax in MAD |
Tmax is summarized by dosing regimen |
Day 4, Day 6, Day 8 (Pre dose to 24 hours) |
|
Secondary |
Plasma concentration of each dose of study drug to determine Tlast in MAD |
Tlast is the time of last measurable concentration |
Day 4, Day 6, Day 8 |
|
Secondary |
Plasma concentration of each dose of study drug to determine Clast in MAD |
Clast is the last measurable concentration (above the quantification limit) |
Day 4, Day 6, Day 8 |
|
Secondary |
Plasma concentration of each dose of study drug to determine Ctau in MAD |
Ctau is the concentration at the end of dosing interval |
Day 4, Day 6, Day 8 |
|
Secondary |
Plasma concentration of each dose of study drug to determine ?z in MAD |
Individual estimate of terminal elimination rate constant, calculated using log-linear regression of the terminal portions of the plasma concentration-versus-time curves. |
Day 4, Day 6, Day 8 |
|
Secondary |
Plasma concentration of each dose of study drug to determine t1/2 |
t1/2 is summarized by dosing regimen . It is determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline is used in the regression. |
Day 1(0 hours- 24 hours post dose), Day 4, Day 6, Day 8 |
|
Secondary |
Plasma concentration of each dose of study drug to determine Vz/F |
Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. VZ/F after oral dose is influenced by the fraction absorbed. |
Day 4, Day 6, Day 8 |
|